A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction-associated steatotic liver disease.

Although the proportion of MASH cases is greater among patients with decreased FGF21 expression it did not reach statistical significance ( p = .606 based on the G ‐test).

also in 111,027 other papers

However, the three‐way comparison (Table 1 ) yielded borderline significance for fibrosis grades F = 2–4 only.

also in 7,017 other papers

We performed the Kruskal–Wallis test, and based on median scores, the results are borderline significant for NAS and steatosis; however, the data were truly significant for fibrosis (Table 1 ).

also in 11,409 other papers